Parabilis Medicines, Inc.
PBLS
$28.80
$2.449.26%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -18.24% | ||||
| Total Depreciation and Amortization | -7.34% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 14.88% | ||||
| Change in Net Operating Assets | -964.64% | ||||
| Cash from Operations | -44.05% | ||||
| Capital Expenditure | -398.65% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -105.52% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -2,688.57% | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | 352.28% | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 79,720.97% | ||||
| Cash from Financing | 421.48% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 656.65% | ||||